Prostatic artery embolization for palliative control of hematuria in locally advanced or metastatic prostate cancer: a systematic review.
TL;DR
PAE offers rapid, low-risk palliation for advanced prostate cancer symptoms, and while it is a valuable alternative for high-risk patients, comparative trials are needed to define its role in obstruction and pain management.
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Prostate Cancer Diagnosis and Treatment
Genital Health and Disease
PAE offers rapid, low-risk palliation for advanced prostate cancer symptoms, and while it is a valuable alternative for high-risk patients, comparative trials are needed to define its role in obstruct
- 연구 설계 systematic review
APA
Shahin Dehvari, Iman Razipour, et al. (2026). Prostatic artery embolization for palliative control of hematuria in locally advanced or metastatic prostate cancer: a systematic review.. Abdominal radiology (New York), 51(5), 2583-2595. https://doi.org/10.1007/s00261-025-05250-x
MLA
Shahin Dehvari, et al.. "Prostatic artery embolization for palliative control of hematuria in locally advanced or metastatic prostate cancer: a systematic review.." Abdominal radiology (New York), vol. 51, no. 5, 2026, pp. 2583-2595.
PMID
41134363
Abstract
[PURPOSE] Prostatic artery embolization (PAE) has emerged as a minimally invasive option for the palliative control of hematuria in locally advanced or metastatic prostate cancer. This systematic review focuses on the efficacy and safety of PAE for this indication, while also synthesizing available data on secondary outcomes such as urinary retention and pain.
[METHODS] A comprehensive search of PubMed/MEDLINE, Scopus, and Web of Science identified eight primary studies (four retrospective case series, one prospective cohort, and three case reports). Methodological quality was assessed using Joanna Briggs Institute (JBI) checklists and the Newcastle-Ottawa Scale (NOS).
[RESULTS] PAE demonstrated high technical success (89-100%) and immediate hemostatic control (67-100%), with durable symptom relief in most patients. Functional improvements in urinary retention (50-80% catheter-free rates) and pain (≈ 70% improvement) were observed, though outcomes varied. Major complications were rare (< 3%), supporting PAE's safety over traditional options like TURP (higher bleeding risk) or EBRT (delayed response).
[CONCLUSION] PAE offers rapid, low-risk palliation for advanced prostate cancer symptoms. While it is a valuable alternative for high-risk patients, comparative trials are needed to define its role in obstruction and pain management.
[METHODS] A comprehensive search of PubMed/MEDLINE, Scopus, and Web of Science identified eight primary studies (four retrospective case series, one prospective cohort, and three case reports). Methodological quality was assessed using Joanna Briggs Institute (JBI) checklists and the Newcastle-Ottawa Scale (NOS).
[RESULTS] PAE demonstrated high technical success (89-100%) and immediate hemostatic control (67-100%), with durable symptom relief in most patients. Functional improvements in urinary retention (50-80% catheter-free rates) and pain (≈ 70% improvement) were observed, though outcomes varied. Major complications were rare (< 3%), supporting PAE's safety over traditional options like TURP (higher bleeding risk) or EBRT (delayed response).
[CONCLUSION] PAE offers rapid, low-risk palliation for advanced prostate cancer symptoms. While it is a valuable alternative for high-risk patients, comparative trials are needed to define its role in obstruction and pain management.
MeSH Terms
Humans; Male; Hematuria; Prostatic Neoplasms; Palliative Care; Embolization, Therapeutic; Prostate